Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

• Status: Completed
• Trial end date: 2003-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• 18 years or older.

• Diagnosis of open-angle glaucoma or ocular hypertension.

• LogMAR visual acuity not worse than 0.6.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Clinically relevant ophthalmic or systemic conditions.

• Other protocol-defined exclusion criteria may apply.